TP-271

DB15040InvestigationalSmall molecule

TP-271 is under investigation in clinical trial NCT02724085 (A Phase 1 Study to Assess the Safety, Tolerability and PK of IV TP-271).

Formula / weight: C₂₇H₃₁FN₄O₈ · 558.563 g/mol (avg)
Code names: TP-271

Resolves to

Compound

UNIIY6IUM7395QCAS1207284-17-0ChEMBLCHEMBL2057236

Structure

InChIKeyIXMIZHVJXGKPJI-HMFHYXQTSA-NSMILES[H][C@@]12CC3=C(F)C=C(NC(=O)[C@@H]4CCCN4C)C(O)=C3C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2

What you can answer from here — as of April 23, 2025

2Clinical trialsPhase, status and sponsor resolved per trial

Which companies are running trials of TP-271, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account